RESUMEN
: Vascularized composite allotransplantation (VCA) is a relatively new field in reconstructive medicine. Likely a result of the unique tissue composition of these allografts-including skin and often a bone marrow component-the immunology and rejection patterns do not always mimic those of the well-studied solid organ transplantations. While the number and type of VCAs performed is rapidly expanding, there is still much to be discovered and understood in the field. With more patients, new findings and patterns emerge and add to our understanding of VCA. Here, we present a case report of an upper extremity transplant recipient with trauma-induced rejection.
Asunto(s)
Amputación Traumática/cirugía , Brazo/trasplante , Traumatismos por Explosión/cirugía , Rechazo de Injerto/diagnóstico , Alotrasplante Compuesto Vascularizado , Humanos , Inmunosupresores/uso terapéutico , Masculino , Estados Unidos , VeteranosAsunto(s)
Pared Abdominal/cirugía , Trasplante de Pene , Escroto/trasplante , Alotrasplante Compuesto Vascularizado/métodos , Traumatismos Abdominales/cirugía , Adulto , Humanos , Procesamiento de Imagen Asistido por Computador , Masculino , Pene/irrigación sanguínea , Pene/lesiones , Procedimientos de Cirugía Plástica/métodos , Escroto/lesionesRESUMEN
Next-generation tissue-based biomarkers for immunotherapy will likely include the simultaneous analysis of multiple cell types and their spatial interactions, as well as distinct expression patterns of immunoregulatory molecules. Here, we introduce a comprehensive platform for multispectral imaging and mapping of multiple parameters in tumor tissue sections with high-fidelity single-cell resolution. Image analysis and data handling components were drawn from the field of astronomy. Using this "AstroPath" whole-slide platform and only six markers, we identified key features in pretreatment melanoma specimens that predicted response to anti-programmed cell death-1 (PD-1)-based therapy, including CD163+PD-L1- myeloid cells and CD8+FoxP3+PD-1low/mid T cells. These features were combined to stratify long-term survival after anti-PD-1 blockade. This signature was validated in an independent cohort of patients with melanoma from a different institution.